References
O’Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G, Gudmundsson A, Cruz-Jentoft AJ, Knol W, Bahat G, van der Velde N, Petrovic M, Curtin D (2023) STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med 14(4):625–632
British National Formulary 81 (2021). BMJ Group & Pharmaceutical Press, London, pp 767–773
https://www.uspharmacist.com/article/bisphosphonate-nephrotoxicity-risks-and-use-in-ckd-patients. Accessed 15 Jan 2024
https://www.ema.europa.eu/en/documents/product-information/ebixa-epar-product-information_en.pdf. Accessed 15 Jan 2024
Evans M, Morgan AR, Davies S, Beba H, Strain WD (2022) The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing 51(10):afac201
Shrestha DB, Budhathoki P, Sedhai YR, Karki P, Gurung S, Raut S, Damonte JI, Del Buono MG, Mojadidi MK, Elgendy IY, Patel T, Patel NK (2021) Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated systematic review and meta-analysis of 13 randomized clinical trials including 14,618 patients with heart failure. J Cardiovasc Pharmacol 78(4):501–514
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 44(37):3627–3639
Seppala LJ, Petrovic M, Ryg J, Bahat G, Topinkova E, Szczerbińska K, van der Cammen TJM, Hartikainen S, Ilhan B, Landi F, Morrissey Y, Mair A, Gutiérrez-Valencia M, Emmelot-Vonk MH, Mora MÁC, Denkinger M, Crome P, Jackson SHD, Correa-Pérez A, Knol W, Soulis G, Gudmundsson A, Ziere G, Wehling M, O’Mahony D, Cherubini A, van der Velde N (2021) STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age Ageing 50(4):1189–1199
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
For this type of study formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
O’Mahony, D., Cherubini, A., Guiteras, A.R. et al. Response to letter by Masse O et al. STOPP/START version 3: clinical pharmacists are raising alarms. Eur Geriatr Med 15, 593–596 (2024). https://doi.org/10.1007/s41999-024-00958-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s41999-024-00958-3